%0 Journal Article
%A Haeckert, Jan
%A Roeh, Astrid
%A Karch, Susanne
%A Koeglsperger, Thomas
%A Hasan, Alkomiet
%A Papazova, Irina
%T Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation.
%J Pharmacopsychiatry
%V 58
%N 1
%@ 0176-3679
%C Stuttgart [u.a.]
%I Thieme
%M DZNE-2025-00029
%P 5 - 13
%D 2025
%X This study evaluates the impact of Parkinson disease (PD) medication in advanced PD on neuropsychological performance, psychiatric symptoms, impulsivity and the quality of life. In the 4-year period 27 patients with advanced PD, scheduled for deep brain stimulation (DBS) surgery (N=27, mean age: 58.9±7.1, disease duration: 10.0 years±4.2) were examined preoperatively. We hypothesized that a high dosage of PD medication or current use of dopamine agonists affect cognitive functioning and psychiatric wellbeing.We performed two subgroup analyses with low versus high levodopa-equivalent Dosage (LED) medication and without versus with dopaminagonistic medication.The neuropsychological testing revealed significant differences in the verbal learn- and memory-test (VLMT) during the learning passage (U=36.500, Z=- 2.475, p=0.012) and in the subtest of the semantic fluency of Regensburg verbal fluency test (RWT) (t(25)=- 2.066, p=0.049) with better results for patients without dopaminagonistic medication. Pearson correlation analyses of LED in correlation with the clinical and cognitive dependent variables showed a significant higher PANSS total score in patients with higher LED medication (r=0.491, p=0.009). In addition, lower LED treatment was associated with significant higher scores in the impulsivity perseverance subtest (r=- 0.509, p=0.008).In conclusion, we found lower LEDs to be correlated with a better perseverance in the impulsivity test and additional treatment with a dopamine agonist influenced some verbal learning tasks and the PANSS total score in patients with advanced PD. This should be considered prior to DBS surgery.
%K Humans
%K Parkinson Disease: drug therapy
%K Parkinson Disease: psychology
%K Parkinson Disease: complications
%K Parkinson Disease: therapy
%K Deep Brain Stimulation
%K Male
%K Middle Aged
%K Female
%K Neuropsychological Tests
%K Aged
%K Antiparkinson Agents: therapeutic use
%K Quality of Life
%K Dopamine Agonists: therapeutic use
%K Levodopa: therapeutic use
%K Cognition: drug effects
%K Antiparkinson Agents (NLM Chemicals)
%K Dopamine Agonists (NLM Chemicals)
%K Levodopa (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39572152
%R 10.1055/a-2446-6877
%U https://pub.dzne.de/record/274048